Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dovitinib plus Fulvestrant in HR+/HER2- Breast Cancer
NCT01528345Phase 2Terminated
- Sponsor
- Novartis
- Start
- Apr 2012
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 2 trial of dovitinib in breast cancer, sponsored by Novartis. Started Apr 2012; status: terminated.
02
Drugs
dovitinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01528345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01528345.